Skip to main content

Advertisement

Log in

Multifaceted roles of PGE2 in inflammation and cancer

Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

Prostaglandin E2 (PGE2) is a bioactive lipid that elicits a wide range of biological effects associated with inflammation and cancer. PGE2 exerts diverse effects on cell proliferation, apoptosis, angiogenesis, inflammation, and immune surveillance. This review concentrates primarily on gastrointestinal cancers, where the actions of PGE2 are most prominent, most likely due to the constant exposure to dietary and environmental insults and the intrinsic role of PGE2 in tissue homeostasis. A discussion of recent efforts to elucidate the complex and interconnected pathways that link PGE2 signaling with inflammation and cancer is provided, supported by the abundant literature showing a protective effect of NSAIDs and the therapeutic efficacy of targeting mPGES-1 or EP receptors for cancer prevention. However, suppressing PGE2 formation as a means of providing chemoprotection against all cancers may not ultimately be tenable, undoubtedly the situation for patients with inflammatory bowel disease. Future studies to fully understand the complex role of PGE2 in both inflammation and cancer will be required to develop novel strategies for cancer prevention that are both effective and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS et al (2003) Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24(2):307–315

    Article  PubMed  CAS  Google Scholar 

  2. Dong M, Johnson M, Rezaie A, Ilsley JN, Nakanishi M, et al. (2005) Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 11(6):2265–71

    Google Scholar 

  3. Ilsley JN, Nakanishi M, Flynn C, Belinsky GS, De Guise S et al (2005) Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 65(7):2636–2643

    Article  PubMed  CAS  Google Scholar 

  4. Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55(1):115–122

    Article  PubMed  CAS  Google Scholar 

  5. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548):1871–1875

    Article  PubMed  CAS  Google Scholar 

  6. Smith WL (1989) The eicosanoids and their biochemical mechanisms of action. Biochem J 259(2):315–324

    PubMed  CAS  Google Scholar 

  7. Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445–1461

    Article  PubMed  CAS  Google Scholar 

  8. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96(13):7220–7225

    Article  PubMed  CAS  Google Scholar 

  9. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y et al (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275(42):32783–32792

    Article  PubMed  CAS  Google Scholar 

  10. Tai HH, Cho H, Tong M, Ding Y (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 12(8):955–962

    Article  PubMed  CAS  Google Scholar 

  11. Yan M, Rerko RM, Platzer P, Dawson D, Willis J et al (2004) 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 101(50):17468–17473

    Article  PubMed  CAS  Google Scholar 

  12. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH et al (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280(5):3217–3223

    Article  PubMed  CAS  Google Scholar 

  13. Ding Y, Tong M, Liu S, Moscow JA, Tai HH (2005) NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26(1):65–72

    Article  PubMed  CAS  Google Scholar 

  14. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J et al (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 106(23):9409–9413

    Article  PubMed  CAS  Google Scholar 

  15. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K et al (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 103(32):12098–12102

    Article  PubMed  CAS  Google Scholar 

  16. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T et al (2008) Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 68(22):9331–9337

    Article  PubMed  CAS  Google Scholar 

  17. Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46(2):205–229

    PubMed  CAS  Google Scholar 

  18. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282(16):11613–11617

    Article  PubMed  CAS  Google Scholar 

  19. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661–690

    Article  PubMed  CAS  Google Scholar 

  20. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59(3):207–224

    Article  PubMed  CAS  Google Scholar 

  21. Kalinski P (2012) Regulation of immune responses by prostaglandin e2. J Immunol 188(1):21–28

    Article  PubMed  CAS  Google Scholar 

  22. Sakata D, Yao C, Narumiya S (2010) Prostaglandin E2, an immunoactivator. J Pharmacol Sci 112(1):1–5

    Article  PubMed  CAS  Google Scholar 

  23. Wallace JL (2001) Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin N Am 30(4):971–980

    Article  CAS  Google Scholar 

  24. Uematsu S, Matsumoto M, Takeda K, Akira S (2002) Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 168(11):5811–5816

    PubMed  CAS  Google Scholar 

  25. Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y et al (2010) Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie 92(6):651–659

    Article  PubMed  CAS  Google Scholar 

  26. Kojima F, Kapoor M, Yang L, Fleishaker EL, Ward MR et al (2008) Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol 180(12):8361–8368

    PubMed  CAS  Google Scholar 

  27. Wang M, Song WL, Cheng Y, Fitzgerald GA (2008) Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med 263(5):500–505

    Article  PubMed  CAS  Google Scholar 

  28. Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34(2):149–162

    Article  PubMed  CAS  Google Scholar 

  29. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–957

    Article  PubMed  CAS  Google Scholar 

  30. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ et al (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206(3):535–548

    Article  PubMed  CAS  Google Scholar 

  31. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56(8):2608–2619

    Article  PubMed  CAS  Google Scholar 

  32. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M et al (2007) The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23– > IL-17 axis. J Immunol 178(12):8138–8147

    PubMed  CAS  Google Scholar 

  33. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD (2005) Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 174(8):5033–5039

    PubMed  CAS  Google Scholar 

  34. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ et al (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5(6):698–701

    Article  PubMed  CAS  Google Scholar 

  35. Wallace JL (2006) COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World J 6:577–588

    Article  CAS  Google Scholar 

  36. Yin H, Cheng L, Langenbach R, Ju C (2007) Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 45(1):159–169

    Article  PubMed  CAS  Google Scholar 

  37. Scher JU, Pillinger MH (2009) The anti-inflammatory effects of prostaglandins. J Investig Med 57(6):703–708

    PubMed  CAS  Google Scholar 

  38. Joshi PC, Zhou X, Cuchens M, Jones Q (2001) Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol 166(2):885–891

    PubMed  CAS  Google Scholar 

  39. Linnemeyer PA, Pollack SB (1993) Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J Immunol 150(9):3747–3754

    PubMed  CAS  Google Scholar 

  40. Martinet L, Jean C, Dietrich G, Fournie JJ, Poupot R (2010) PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 80(6):838–845

    Article  PubMed  CAS  Google Scholar 

  41. Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E et al (2003) Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol 10(4):469–479

    Article  PubMed  Google Scholar 

  42. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D et al (2010) PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116(9):1454–1459

    Article  PubMed  CAS  Google Scholar 

  43. Betz M, Fox BS (1991) Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146(1):108–113

    PubMed  CAS  Google Scholar 

  44. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML (1993) Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150(12):5321–5329

    PubMed  CAS  Google Scholar 

  45. Allen JE, Wynn TA (2011) Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 7(5):e1002003

    Article  PubMed  CAS  Google Scholar 

  46. Ae T, Ohno T, Hattori Y, Suzuki T, Hosono K et al (2010) Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers. Am J Physiol Gastrointest Liver Physiol 299(5):G1139–G1146

    Article  PubMed  CAS  Google Scholar 

  47. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T et al (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109(7):883–893

    PubMed  CAS  Google Scholar 

  48. Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC et al (2011) Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) 4(8):1198–1208

    Article  CAS  Google Scholar 

  49. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453(7193):314–321

    Article  PubMed  CAS  Google Scholar 

  50. Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV et al (2010) cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci 117(1):122–132

    Article  PubMed  CAS  Google Scholar 

  51. Iizuka M, Konno S (2011) Wound healing of intestinal epithelial cells. World J Gastroenterol: WJG 17(17):2161–2171

    Article  PubMed  Google Scholar 

  52. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310(5753):1504–1510

    Article  PubMed  CAS  Google Scholar 

  53. Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278(37):35451–35457

    Article  PubMed  CAS  Google Scholar 

  54. Nakanishi M, Sato T, Li Y, Nelson AJ, Farid M et al (2012) Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts. Am J Respir Cell Mol Biol 46(2):217–223

    Article  PubMed  CAS  Google Scholar 

  55. Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M (2008) Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 283(28):19864–19871

    Article  PubMed  CAS  Google Scholar 

  56. Zhang Y, Daaka Y (2011) PGE2 promotes angiogenesis through EP4 and PKA Cgamma pathway. Blood 118(19):5355–5364

    Article  PubMed  CAS  Google Scholar 

  57. Zhu Z, Fu C, Li X, Song Y, Li C et al (2011) Prostaglandin E2 promotes endothelial differentiation from bone marrow-derived cells through AMPK activation. PLoS One 6(8):e23554

    Article  PubMed  CAS  Google Scholar 

  58. Rao R, Redha R, Macias-Perez I, Su Y, Hao C et al (2007) Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282(23):16959–16968

    Article  PubMed  CAS  Google Scholar 

  59. Sipos F, Valcz G, Molnar B (2012) Physiological and pathological role of local and immigrating colonic stem cells. World J Gastroenterol: WJG 18(4):295–301

    Article  PubMed  Google Scholar 

  60. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ et al (2003) Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29(5):537–544

    Article  PubMed  CAS  Google Scholar 

  61. Walker NM, Badri LN, Wadhwa A, Wettlaufer S, Peters-Golden M et al (2012) Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 185(1):77–84

    Article  PubMed  CAS  Google Scholar 

  62. McCann MR, Monemdjou R, Ghassemi-Kakroodi P, Fahmi H, Perez G et al (2011) mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther 13(1):R6

    Article  PubMed  CAS  Google Scholar 

  63. Iwanaga K, Okada M, Murata T, Hori M, Ozaki H (2012) Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation. J Pharmacol Exp Ther 340(3):604–611

    Article  PubMed  CAS  Google Scholar 

  64. Harding P, LaPointe MC (2011) Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor. Prostaglandins Leukot Essent Fat Acids 84(5–6):147–152

    Article  CAS  Google Scholar 

  65. Ayabe S, Murata T, Maruyama T, Hori M, Ozaki H (2009) Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors. Br J Pharmacol 156(5):835–845

    Article  PubMed  CAS  Google Scholar 

  66. Fischer SM, Hawk ET, Lubet RA (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res 4(11):1728–1735

    Article  CAS  Google Scholar 

  67. Waddell WR, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157(1):175–179

    Article  PubMed  CAS  Google Scholar 

  68. Waddell WR, Loughry RW (1983) Sulindac for polyposis of the colon. J Surg Oncol 24(1):83–87

    Article  PubMed  CAS  Google Scholar 

  69. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD et al (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83(5):355–358

    Article  PubMed  CAS  Google Scholar 

  70. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325(23):1593–1596

    Article  PubMed  CAS  Google Scholar 

  71. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24(5):985–990

    Article  PubMed  CAS  Google Scholar 

  72. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65(5):1822–1829

    Article  PubMed  CAS  Google Scholar 

  73. Wilson JW, Potten CS (2000) The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 60(16):4645–4653

    PubMed  CAS  Google Scholar 

  74. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS et al (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68(9):3251–3259

    Article  PubMed  CAS  Google Scholar 

  75. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L et al (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121(6):1339–1347

    Article  PubMed  CAS  Google Scholar 

  76. Guda K, Upender MB, Belinsky G, Flynn C, Nakanishi M et al (2004) Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23(21):3813–3821

    Article  PubMed  CAS  Google Scholar 

  77. Nambiar PR, Nakanishi M, Gupta R, Cheung E, Firouzi A et al (2004) Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res 64(18):6394–6401

    Article  PubMed  CAS  Google Scholar 

  78. Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW (2000) Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21(8):1567–1572

    Article  PubMed  CAS  Google Scholar 

  79. Chen EP, Smyth EM (2011) COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat 96(1–4):14–20

    Article  PubMed  CAS  Google Scholar 

  80. Markosyan N, Chen EP, Ndong VN, Yao Y, Sterner CJ et al (2011) Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 32(10):1441–1449

    Article  PubMed  CAS  Google Scholar 

  81. Oshima H, Oshima M, Inaba K, Taketo MM (2004) Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23(7):1669–1678

    Article  PubMed  CAS  Google Scholar 

  82. Itadani H, Oshima H, Oshima M, Kotani H (2009) Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics 10:615

    Article  PubMed  CAS  Google Scholar 

  83. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM et al (2006) Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 131(4):1086–1095

    Article  PubMed  CAS  Google Scholar 

  84. Oshima H, Oguma K, Du YC, Oshima M (2009) Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. Cancer Sci 100(10):1779–1785

    Article  PubMed  CAS  Google Scholar 

  85. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M et al (2002) Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 62(1):28–32

    PubMed  CAS  Google Scholar 

  86. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA et al (2006) Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66(6):3106–3113

    Article  PubMed  CAS  Google Scholar 

  87. Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC et al (2009) Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 9:207

    Article  PubMed  CAS  Google Scholar 

  88. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, Stankova L, Shahin NA et al (2012) MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 13(3):175–183

    Article  PubMed  CAS  Google Scholar 

  89. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S et al (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59(20):5093–5096

    PubMed  CAS  Google Scholar 

  90. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T et al (2004) Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53(8):1151–1158

    Article  PubMed  CAS  Google Scholar 

  91. Xia D, Wang D, Kim SH, Katoh H, DuBois RN (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 18(2):224–226

    Article  PubMed  CAS  Google Scholar 

  92. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F et al (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7(9):1048–1051

    Article  PubMed  CAS  Google Scholar 

  93. Jimenez P, Piazuelo E, Cebrian C, Ortego J, Strunk M et al (2010) Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 31(3):440–451

    Article  PubMed  CAS  Google Scholar 

  94. Jin J, Chang Y, Wei W, He YF, Hu SS et al (2012) Prostanoid EP1 receptor as the target of (−)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin 33(5):701–709

    Article  PubMed  CAS  Google Scholar 

  95. Amano H, Ito Y, Suzuki T, Kato S, Matsui Y et al (2009) Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci 100(12):2318–2324

    Article  PubMed  CAS  Google Scholar 

  96. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392–401

    Article  PubMed  CAS  Google Scholar 

  97. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM (2012) Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 35(2):179–188

    Article  PubMed  CAS  Google Scholar 

  98. Liu L, Ge D, Ma L, Mei J, Liu S et al (2012) Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7(7):1091–1100

    Article  PubMed  CAS  Google Scholar 

  99. Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM (2006) Regulating the immune response to tumours. Adv Drug Deliv Rev 58(8):948–961

    Article  PubMed  CAS  Google Scholar 

  100. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499–4506

    Article  PubMed  CAS  Google Scholar 

  101. Izcue A, Coombes JL, Powrie F (2009) Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27:313–338

    Article  PubMed  CAS  Google Scholar 

  102. Fehervari Z, Sakaguchi S (2004) CD4+ Tregs and immune control. J Clin Investig 114(9):1209–1217

    PubMed  CAS  Google Scholar 

  103. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N et al (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175(3):1483–1490

    PubMed  CAS  Google Scholar 

  104. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B et al (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65(12):5211–5220

    Article  PubMed  CAS  Google Scholar 

  105. Yuan XL, Chen L, Li MX, Dong P, Xue J et al (2010) Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 134(3):277–288

    Article  PubMed  CAS  Google Scholar 

  106. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM et al (2008) Enhanced functionality of CD4 + CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14(4):1032–1040

    Article  CAS  Google Scholar 

  107. Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY et al (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32(1):22–28

    Article  PubMed  CAS  Google Scholar 

  108. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Jackson EK et al (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 285(36):27571–27580

    Article  PubMed  CAS  Google Scholar 

  109. Soontrapa K, Honda T, Sakata D, Yao C, Hirata T et al (2011) Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci U S A 108(16):6668–6673

    Article  PubMed  CAS  Google Scholar 

  110. Pinchuk IV, Beswick EJ, Saada JI, Boya G, Schmitt D et al (2011) Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology 140(7):2019–2030

    Article  PubMed  CAS  Google Scholar 

  111. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174

    Article  PubMed  CAS  Google Scholar 

  112. Lu T, Gabrilovich DI. (2012) Molecular Pathways : Tumor Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res 18(18):1–6

    Google Scholar 

  113. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–268

    Article  PubMed  CAS  Google Scholar 

  114. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20):5498–5505

    Article  PubMed  CAS  Google Scholar 

  115. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470

    Article  PubMed  CAS  Google Scholar 

  116. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67(9):4507–4513

    Article  PubMed  CAS  Google Scholar 

  117. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J et al (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553–1560

    Article  PubMed  CAS  Google Scholar 

  118. Li Y, Yin S, Nie D, Xie S, Ma L et al (2011) MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis. Int J Hematol 94(5):472–478

    Article  PubMed  CAS  Google Scholar 

  119. Deckmann K, Rorsch F, Geisslinger G, Grosch S (2012) Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-kappaB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1. Cell Signal 24(2):460–467

    Article  PubMed  CAS  Google Scholar 

  120. Deckmann K, Rorsch F, Steri R, Schubert-Zsilavecz M, Geisslinger G et al (2010) Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-kappaB. Biochem Pharmacol 80(9):1365–1372

    Article  PubMed  CAS  Google Scholar 

  121. Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S et al (2008) Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326(3):975–982

    Article  PubMed  CAS  Google Scholar 

  122. Cote B, Boulet L, Brideau C, Claveau D, Ethier D et al (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17(24):6816–6820

    Article  PubMed  CAS  Google Scholar 

  123. Giroux A, Boulet L, Brideau C, Chau A, Claveau D et al (2009) Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 19(20):5837–5841

    Article  PubMed  CAS  Google Scholar 

  124. Chini MG, De Simone R, Bruno I, Riccio R, Dehm F et al (2012) Design and synthesis of a second series of triazole-based compounds as potent dual mPGES-1 and 5-lipoxygenase inhibitors. Eur J Med Chem 54:311–323

    Article  PubMed  CAS  Google Scholar 

  125. Beales IL, Ogunwobi OO (2010) Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer J Int Cancer 126(9):2247–2255

    CAS  Google Scholar 

  126. Chang HH, Meuillet EJ (2011) Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 3(15):1909–1934

    Article  PubMed  CAS  Google Scholar 

  127. Moon Y, Glasgow WC, Eling TE (2005) Curcumin suppresses interleukin 1beta-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharmacol Exp Ther 315(2):788–795

    Article  PubMed  CAS  Google Scholar 

  128. Koeberle A, Northoff H, Werz O (2009) Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 8(8):2348–2355

    Article  PubMed  CAS  Google Scholar 

  129. Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H et al (2009) Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 388(2):350–354

    Article  PubMed  CAS  Google Scholar 

  130. Koeberle A, Pollastro F, Northoff H, Werz O (2009) Myrtucommulone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br J Pharmacol 156(6):952–961

    Article  PubMed  CAS  Google Scholar 

  131. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545

    Article  PubMed  CAS  Google Scholar 

  132. Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9(4):351–369

    Article  PubMed  CAS  Google Scholar 

  133. Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31(2):249–256

    Article  PubMed  CAS  Google Scholar 

  134. Lewis JD, Deren JJ, Lichtenstein GR (1999) Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin N Am 28(2):459–477, x

    Article  CAS  Google Scholar 

  135. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD et al (2012) Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 143(2):382–389

    Article  PubMed  Google Scholar 

  136. Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140(6):1807–1816

    Article  PubMed  CAS  Google Scholar 

  137. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650–1659

    Article  PubMed  CAS  Google Scholar 

  138. Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9(8):628–638

    Article  PubMed  CAS  Google Scholar 

  139. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES (2001) Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 98(7):3935–3939

    Article  PubMed  CAS  Google Scholar 

  140. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW et al (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60(17):4705–4708

    PubMed  CAS  Google Scholar 

  141. Ishikawa TO, Herschman HR (2010) Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 31(4):729–736

    Article  PubMed  CAS  Google Scholar 

  142. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809

    Article  PubMed  CAS  Google Scholar 

  143. Elander N, Ungerback J, Olsson H, Uematsu S, Akira S et al (2008) Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 372(1):249–253

    Article  PubMed  CAS  Google Scholar 

  144. Sasaki Y, Kamei D, Ishikawa Y, Ishii T, Uematsu S et al (2012) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene 31(24):2943–2952

    Article  PubMed  CAS  Google Scholar 

  145. Okuyama T, Ishihara S, Sato H, Rumi MA, Kawashima K et al (2002) Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. J Lab Clin Med 140(2):92–102

    PubMed  CAS  Google Scholar 

  146. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569

    Article  PubMed  CAS  Google Scholar 

  147. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ et al (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21):10113–10119

    Article  PubMed  CAS  Google Scholar 

  148. Sung YM, He G, Fischer SM (2005) Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 65(20):9304–9311

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are gratefully indebted to Emmanuelle J. Meuillet, PhD, Arizona Cancer Center, University of Arizona for her contribution to this project. This work was supported by NIH grants CA-125691 (DWR), CA-114635 (DWR) and CA-138702 (EM).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel W. Rosenberg.

Additional information

This article is a contribution to the special issue on Inflammation and Cancer - Guest Editor: Takuji Tanaka

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakanishi, M., Rosenberg, D.W. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 35, 123–137 (2013). https://doi.org/10.1007/s00281-012-0342-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-012-0342-8

Keywords

Navigation